U.S. patent application number 12/553483 was filed with the patent office on 2010-02-25 for preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives.
This patent application is currently assigned to Pharmassett, Inc.. Invention is credited to Byoung-Kwon Chun, Jinfa Du, Junxing Shi, Wojciech Stec, Peiyuan Wang.
Application Number | 20100048917 12/553483 |
Document ID | / |
Family ID | 36944864 |
Filed Date | 2010-02-25 |
United States Patent
Application |
20100048917 |
Kind Code |
A1 |
Wang; Peiyuan ; et
al. |
February 25, 2010 |
PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL
PYRIMIDINES AND PURINES AND THEIR DERIVATIVES
Abstract
The present invention provides (i) a process for preparing a
2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii)
conversion of the lactone to nucleosides with potent anti-HCV
activity, and their analogues, and (iii) a method to prepare the
anti-HCV nucleosides containing the
2-deoxy-2-fluoro-2-C-methyl-.beta.-D-ribofuranosyl nucleosides from
a preformed, preferably naturally-occurring, nucleoside.
Inventors: |
Wang; Peiyuan; (Glen Rock,
NJ) ; Stec; Wojciech; (Ksawerow, PL) ; Chun;
Byoung-Kwon; (Robbinsville, NJ) ; Shi; Junxing;
(Duluth, GA) ; Du; Jinfa; (New Hope, PA) |
Correspondence
Address: |
DUANE MORRIS LLP - Atlanta;IP DEPARTMENT
ATLANTIC CENTER PLAZA, 1180 WEST PEACHTREE STREET, NW SUITE 700
ATLANTA
GA
30309-3348
US
|
Assignee: |
Pharmassett, Inc.
Princeton
NJ
|
Family ID: |
36944864 |
Appl. No.: |
12/553483 |
Filed: |
September 3, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11353597 |
Feb 13, 2006 |
7601820 |
|
|
12553483 |
|
|
|
|
11185988 |
Jul 21, 2005 |
|
|
|
11353597 |
|
|
|
|
60608230 |
Sep 9, 2004 |
|
|
|
60589866 |
Jul 21, 2004 |
|
|
|
Current U.S.
Class: |
549/214 |
Current CPC
Class: |
C07D 307/62 20130101;
C07D 405/04 20130101; C07H 19/12 20130101; C07D 473/34 20130101;
C07D 307/33 20130101; C07H 19/16 20130101 |
Class at
Publication: |
549/214 |
International
Class: |
C07D 307/02 20060101
C07D307/02 |
Claims
1-18. (canceled)
19. A
3,5-di-O-protected-2-deoxy-2-fluoro-2-C-methyl-D-ribono-.gamma.-lac-
tone of the following general formula: ##STR00013## wherein R.sup.3
and R.sup.5 can be independently H, CH.sub.3, or acyl;
alternatively, R.sup.3' and R.sup.5' are linked through
--SiR.sub.2--O--SiR.sub.2-- or --SiR.sub.2--, wherein R is a lower
alkyl such as CH.sub.3, ethyl, and n-Pr or I-Pr.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/353,597, filed Feb. 13, 2006, which is a
continuation of U.S. patent application Ser. No. 11/185,988, filed
Jul. 21, 2005, which claims priority to U.S. Provisional
Application Nos. 60/608,230 and 60/589,866, filed Sep. 9, 2004 and
Jul. 21, 2004 and which are assigned to the same assignee as this
application. The aforementioned patent applications are expressly
incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention provides (i) a process for preparing a
2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii)
conversion of the lactone to nucleosides with potent anti-HCV
activity, and their analogues, and (iii) a method to prepare the
anti-HCV nucleosides containing the
2'-deoxy-2'-fluoro-2'-C-methyl-.beta.-D-ribofuranosyl nucleosides
from a preformed, preferably naturally-occurring, nucleoside.
BACKGROUND OF THE INVENTION
[0003] In light of the fact that HCV infection has reached epidemic
levels worldwide, and has tragic effects on the infected patients.
Presently there is no universally effective treatment for this
infection and the only drugs available for treatment of chronic
hepatitis C are various forms of alpha interferon (IFN-.alpha.),
either alone or in combination with ribavirin. However, the
therapeutic value of these treatments has been compromised largely
due to adverse effects, which highlights the need for development
of additional options for treatment.
[0004] HCV is a small, enveloped virus in the Flaviviridae family,
with a positive single-stranded RNA genome of .about.9.6 kb within
the nucleocapsid. The genome contains a single open reading frame
(ORF) encoding a polyprotein of just over 3,000 amino acids, which
is cleaved to generate the mature structural and nonstructural
viral proteins. ORF is flanked by 5' and 3' non-translated regions
(NTRs) of a few hundred nucleotides in length, which are important
for RNA translation and replication. The translated polyprotein
contains the structural core (C) and envelope proteins (E1, E2, p7)
at the N-terminus, followed by the nonstructural proteins (NS2,
NS3, NS4A, NS4B, NS5A, NS5B). The mature structural proteins are
generated via cleavage by the host signal peptidase. The junction
between NS2 and NS3 is autocatalytically cleaved by the NS2/NS3
protease, while the remaining four junctions are cleaved by the
N-terminal serine protease domain of NS3 complexed with NS4A. The
NS3 protein also contains the NTP-dependent helicase activity which
unwinds duplex RNA during replication. The NS5B protein possesses
RNA-dependent RNA polymerase (RDRP) activity, which is essential
for viral replication. It is emphasized here that, unlike HBV or
HIV, no DNA is involved in the replication of HCV.
[0005] U.S. patent application (Ser. No. 10/828,753) discloses that
1-(2-deoxy-2-fluoro-2-C-methyl-.beta.-D-ribofuranosyl)cytosine (14)
is a potent and selective anti-HCV agent. The original synthetic
procedures (Schemes 1-3) are quite inefficient, with overall yields
at or below 4% and are not amenable to large-scale.
##STR00001##
##STR00002##
##STR00003##
[0006] What is needed is a novel and cost effective process for the
synthesis of 2-C-alkyl-2-deoxy-2-substituted-D-ribopyranosyl
nucleosides that have activity against HCV.
SUMMARY OF INVENTION
[0007] The present invention as disclosed herein relates to the
composition and synthetic methods of compounds of general formulas
[I] and [II],
##STR00004##
wherein
[0008] X is halogen (F, Cl, Br),
[0009] Y is N or CH,
[0010] Z is, halogen, OH, OR', SH, SR', NH.sub.2, NHR', or R'
[0011] R.sup.2' is alkyl of C.sub.1-C.sub.3, vinyl, or ethynyl;
[0012] R.sup.3' and R.sup.5' can be same or different H, alkyl,
aralkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or
2',3-O-benzylidene, or 2',3'-cyclic carbonate;
[0013] R.sup.2, R.sup.4, R.sup.5 and R.sup.6 are independently H,
halogen including F, Cl, Br, I, OH, OR', SH, SR', N.sub.3,
NH.sub.2, NHR', NR'.sub.2, NHC(O)OR', lower alkyl of
C.sub.1-C.sub.6, halogenated (F, Cl, Br, I) lower alkyl of
C.sub.1-C.sub.6 such as CF.sub.3 and CH.sub.2CH.sub.2F, lower
alkenyl of C.sub.2-C.sub.6 such as CH.dbd.CH.sub.2, halogenated (F,
Cl, Br, I) lower alkenyl of C.sub.2-C.sub.6 such as CH.dbd.CHCl,
CH.dbd.CHBr and CH.dbd.CHI, lower alkynyl of C.sub.2-C.sub.6 such
as C.ident.CH, halogenated (F, Cl, Br, I) lower alynyl of
C.sub.2-C.sub.6, hydroxy lower alkyl of C.sub.1-C.sub.6 such as
CH.sub.2OH and CH.sub.2CH.sub.2OH, halogenated (F, Cl, Br, I) lower
alkyl of C.sub.1-C.sub.6, lower alkoxy of C.sub.1-C.sub.6 such as
methoxy and ethoxy, CO.sub.2H, CO.sub.2R', CONH.sub.2, CONHR',
CONR'.sub.2, CH.dbd.CHCO.sub.2H, CH.dbd.CHCO.sub.2R'; and, R' is an
optionally substituted alkyl of C.sub.1-C.sub.12 (particularly when
the alkyl is an amino acid residue), cycloalkyl, optionally
substituted alkynyl of C.sub.2-C.sub.6, optionally substituted
lower alkenyl of C.sub.2-C.sub.6, or optionally substituted
acyl.
[0014] In other aspects, the present invention provides methods to
prepare nucleosides containing the
2-deoxy-2-fluoro-2-C-methyl-D-ribofuranosyl moiety of general
structures of III and IV,
##STR00005##
through (i) synthesis of the 3,5-protected
2-deoxy-2-fluoro-2-C-methyl-D-ribono-.quadrature.-lactone
intermediate of general structure V, (ii) conversion of V into
purine and pyrimidine nucleosides of general structures of III and
IV, and (iii) preparation of nucleosides of general structures of
III and IV from preformed, preferably natural, nucleosides.
##STR00006##
Regarding III, IV and V above, R.sup.4 and R.sup.5 are as defined
above and R.sup.3 and R.sup.5 can be independently H, Me, Acyl
(such as Ac, Bz, substituted Bz), benzyl, substituted benzyl,
Trityl, Trialkylsilyl, t-Butyldialkylsilyl, t-Butyldiphenylsilyl,
TIPDS, THP, MOM, MEM, or R.sup.3 and R.sup.5 are linked through
--SiR.sub.2--O--SiR.sub.2-- or --SiR.sub.2--, wherein R is a lower
alkyl group such as Me, Et, n-Pr or i-Pr.
[0015] Still another aspect of the present invention are the novel
lactone intermediates of formula V and processes for the
preparation of the lactone intermediates as detailed below,
including precursor ester intermediates as also detailed below.
DETAILED DESCRIPTION
[0016] Presently no preventive means against Flaviviridae,
including hepatitis C virus (HCV), Dengue virus (DENV), West Nile
virus (WNV) or Yellow Fever virus (YFV), infection is available.
The only approved therapies are for treatment of HCV infection with
alpha interferon alone or in combination with the nucleoside
ribavirin, but the therapeutic value of these treatments has been
compromised largely due to adverse effects. It was recently
discovered that a group of nucleosides, including
2'-deoxy-2'-fluoro-2'-C-methylcytidine (14), exhibit potent and
selective activity against replication of HCV in a replicon system.
However, the difficulty of chemical synthesis of this and analogous
nucleosides impedes further biophysical, biochemical,
pharmacological evaluations mandatory for development of clinical
drugs for treatment of Flaviviridae infection.
[0017] The present invention provides an efficient preparation of
nucleosides containing the
2-deoxy-2-fluoro-2-C-methyl-D-ribofuranosyl moiety III and IV,
through (i) synthesis of intermediate the 3,5-protected
2-deoxy-2-fluoro-2-C-methyl-D-ribono-.gamma.-latone of general
structure V, (ii) conversion of V into purine and pyrimidine
nucleosides of general structures of III and IV, and (iii)
preparation of nucleosides of general structures of III and IV from
preformed, preferably natural, nucleosides.
DEFINITIONS
[0018] The term "independently" is used herein to indicate that the
variable, which is independently applied, varies independently from
application to application. Thus, in a compound such as
R.sup.aXYR.sup.a, wherein R.sup.a is "independently carbon or
nitrogen", both R.sup.a can be carbon, both R.sup.a can be
nitrogen, or one R.sup.a can be carbon and the other R.sup.a
nitrogen.
[0019] As used herein, the terms "enantiomerically pure" or
"enantiomerically enriched" refers to a nucleoside composition that
comprises at least approximately 95%, and preferably approximately
97%, 98%, 99% or 100% of a single enantiomer of that
nucleoside.
[0020] As used herein, the term "substantially free of" or
"substantially in the absence of" refers to a nucleoside
composition that includes at least 85 or 90% by weight, preferably
95% to 98% by weight, and even more preferably 99% to 100% by
weight, of the designated enantiomer of that nucleoside. In a
preferred embodiment, in the methods and compounds of this
invention, the compounds are substantially free of enantiomers.
[0021] The term "alkyl," as used herein, unless otherwise
specified, refers to a saturated straight or branched hydrocarbon
chain of typically C.sub.1 to Cl.sub.10, and specifically includes
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl,
isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl,
cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and
2,3-dimethylbutyl, and the like. The term includes both substituted
and unsubstituted alkyl groups. Alkyl groups can be optionally
substituted with one or more moieties selected from the group
consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy,
aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid,
phosphate, or phosphonate. One or more of the hydrogen atoms
attached to carbon atom on alkyl may be replaces by one or more
halogen atoms, e.g. fluorine or chlorine or both, such as
trifluoromethyl, difluoromethyl, fluorochloromethyl, and the like.
The hydrocarbon chain may also be interrupted by a heteroatom, such
as N, O or S.
[0022] The term "lower alkyl," as used herein, and unless otherwise
specified, refers to a C.sub.1 to C.sub.4 saturated straight or
branched alkyl group, including both substituted and unsubstituted
forms as defined above. Unless otherwise specifically stated in
this application, when alkyl is a suitable moiety, lower alkyl is
preferred. Similarly, when alkyl or lower alkyl is a suitable
moiety, unsubstituted alkyl or lower alkyl is preferred.
[0023] The term "cycloalkyl", as used herein, unless otherwise
specified, refers to a saturated hydrocarbon ring having 3-8 carbon
atoms, preferably, 3-6 carbon atoms, such as cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may
also be substituted on the ring by and alkyl group, such as
cyclopropylmethyl and the like.
[0024] The terms "alkylamino" or "arylamino" refer to an amino
group that has one or two alkyl or aryl substituents,
respectively.
[0025] The term "protected," as used herein and unless otherwise
defined, refers to a group that is added to an oxygen, nitrogen, or
phosphorus atom to prevent its further reaction or for other
purposes. A wide variety of oxygen and nitrogen protecting groups
are known to those skilled in the art of organic synthesis.
Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl,
CH.sub.3, CH.sub.2-alkyl, CH.sub.2-alkenyl, CH.sub.2Ph,
CH.sub.2-aryl, CH.sub.2O-alkyl, CH.sub.2O-aryl, SO.sub.2-alkyl,
SO.sub.2-aryl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl,
and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).
[0026] The term "aryl," as used herein, and unless otherwise
specified, refers to phenyl, biphenyl, or naphthyl, and preferably
phenyl. The term includes both substituted and unsubstituted
moieties. The aryl group can be substituted with one or more
substituents, including, but not limited to hydroxyl, halo, amino,
alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic
acid, sulfate, phosphonic acid, phosphate, or phosphonate, either
unprotected, or protected as necessary, as known to those skilled
in the art, for example, as taught in T. W. Greene and P. G. M.
Wuts, "Protective Groups in Organic Synthesis," 3rd ed., John Wiley
& Sons, 1999.
[0027] The terms "alkaryl" or "alkylaryl" refer to an alkyl group
with an aryl substituent. The terms "aralkyl" or "arylalkyl" refer
to an aryl group with an alkyl substituent, as for example,
benzyl.
[0028] The term "halo," as used herein, includes chloro, bromo,
iodo and fluoro.
[0029] The term "acyl ester" or "O-linked ester" refers to a
carboxylic acid ester of the formula C(O)R' in which the
non-carbonyl moiety of the ester group, R', is a straight or
branched alkyl, or cycloalkyl or lower alkyl, alkoxyalkyl including
methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as
phenoxymethyl, aryl including phenyl optionally substituted with
halogen (F, Cl, Br, I), C.sub.1 to C.sub.4 alkyl or C.sub.1 to
C.sub.4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl
including methanesulfonyl, the mono, di or triphosphate ester,
trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl
(e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in
the esters optimally include a phenyl group.
[0030] The term "acyl" refers to a group of the formula R''C(O)--,
wherein R'' is a straight or branched alkyl, or cycloalkyl, amino
acid, aryl including phenyl, alkylaryl, aralkyl including benzyl,
alkoxyalkyl including methoxymethyl, aryloxyalkyl such as
phenoxymethyl; or substituted alkyl (including lower alkyl), aryl
including phenyl optionally substituted with chloro, bromo, fluoro,
iodo, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy,
sulfonate esters such as alkyl or aralkyl sulphonyl including
methanesulfonyl, the mono, di or triphosphate ester, trityl or
monomethoxy-trityl, substituted benzyl, alkaryl, aralkyl including
benzyl, alkoxyalkyl including methoxymethyl, aryloxyalkyl such as
phenoxymethyl. Aryl groups in the esters optimally comprise a
phenyl group. In particular, acyl groups include acetyl,
trifluoroacetyl, methylacetyl, cyclopropylacetyl, cyclopropyl
carboxy, propionyl, butyryl, hexanoyl, heptanoyl, octanoyl,
neo-heptanoyl, phenylacetyl, 2-acetoxy-2-phenylacetyl,
diphenylacetyl,
.alpha.-methoxy-.alpha.-trifluoromethyl-phenylacetyl, bromoacetyl,
2-nitro-benzeneacetyl, 4-chloro-benzeneacetyl,
2-chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl,
trimethylacetyl, chlorodifluoroacetyl, perfluoroacetyl,
fluoroacetyl, bromodifluoroacetyl, methoxyacetyl,
2-thiopheneacetyl, chlorosulfonylacetyl, 3-methoxyphenylacetyl,
phenoxyacetyl, tert-butylacetyl, trichloroacetyl,
monochloro-acetyl, dichloroacetyl, 7H-dodecafluoro-heptanoyl,
perfluoro-heptanoyl, 7H-dodeca-fluoroheptanoyl,
7-chlorododecafluoro-heptanoyl, 7-chloro-dodecafluoro-heptanoyl,
7H-dodecafluoroheptanoyl, 7H-dodeca-fluoroheptanoyl,
nona-fluoro-3,6-dioxa-heptanoyl, nonafluoro-3,6-dioxaheptanoyl,
perfluoroheptanoyl, methoxybenzoyl, methyl
3-amino-5-phenylthiophene-2-carboxyl,
3,6-dichloro-2-methoxy-benzoyl,
4-(1,1,2,2-tetrafluoro-ethoxy)-benzoyl, 2-bromo-propionyl,
omega-aminocapryl, decanoyl, n-pentadecanoyl, stearyl,
3-cyclopentyl-propionyl, 1-benzene-carboxyl, O-acetylmandelyl,
pivaloyl acetyl, 1-adamantane-carboxyl, cyclohexane-carboxyl,
2,6-pyridinedicarboxyl, cyclopropane-carboxyl,
cyclobutane-carboxyl, perfluorocyclohexyl carboxyl,
4-methylbenzoyl, chloromethyl isoxazolyl carbonyl,
perfluorocyclohexyl carboxyl, crotonyl,
1-methyl-1H-indazole-3-carbonyl, 2-propenyl, isovaleryl,
1-pyrrolidinecarbonyl, 4-phenylbenzoyl. When the term acyl is used,
it is meant to be a specific and independent disclosure of acetyl,
trifluoroacetyl, methylacetyl, cyclopropylacetyl, propionyl,
butyryl, hexanoyl, heptanoyl, octanoyl, neo-heptanoyl,
phenylacetyl, diphenylacetyl, ct-trifluoromethyl-phenylacetyl,
bromoacetyl, 4-chloro-benzeneacetyl, 2-chloro-2,2-diphenylacetyl,
2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl,
perfluoroacetyl, fluoroacetyl, bromodifluoroacetyl,
2-thiopheneacetyl, tert-butylacetyl, trichloroacetyl,
monochloro-acetyl, dichloroacetyl, methoxybenzoyl,
2-bromo-propionyl, decanoyl, n-pentadecanoyl, stearyl,
3-cyclopentyl-propionyl, 1-benzene-carboxyl, pivaloyl acetyl,
1-adamantane-carboxyl, cyclohexane-carboxyl,
2,6-pyridinedicarboxyl, cyclopropane-carboxyl,
cyclobutane-carboxyl, 4-methylbenzoyl, crotonyl,
1-methyl-1H-indazole-3-carbonyl, 2-propenyl, isovaleryl,
4-phenylbenzoyl.
[0031] The term "lower acyl" refers to an acyl group in which R'',
above defined, is lower alkyl.
[0032] The term "purine" or "pyrimidine" base includes, but is not
limited to, adenine, N.sup.6-alkylpurines, N.sup.6-acylpurines
(wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl),
N.sup.6-benzylpurine, N.sup.6-halopurine, N.sup.6-vinylpurine,
N.sup.6-acetylenic purine, N.sup.6-acyl purine,
N.sup.6-hydroxyalkyl purine, N.sup.6-allcylaminopurine,
N.sup.6-thioallcyl purine, N.sup.2-alkylpurines,
N.sup.2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine,
5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2-
and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including
5-fluorouracil, C.sup.5-alkylpyrimidines,
C.sup.5-benzylpyrimidines, C.sup.5-halopyrimidines,
C.sup.5-vinylpyrimidine, C.sup.5-acetylenic pyrimidine,
C.sup.5-acyl pyrimidine, C.sup.5-hydroxyalkyl purine,
C.sup.5-amidopyrimidine, C.sup.5-cyanopyrimidine,
C.sup.5-iodopyrimidine, C.sup.6-lodo-pyrimidine, C.sup.5--Br-vinyl
pyrimidine, C.sup.6--Br-vinyl pyrimidine, C.sup.5-nitropyrimidine,
C.sup.5-amino-pyrimidine, N.sup.2-alkylpurines,
N.sup.2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl,
triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and
pyrazolopyrimidinyl. Purine bases include, but are not limited to,
guanine, adenine, hypoxanthine, 2,6-diaminopurine, and
6-chloropurine. Functional oxygen and nitrogen groups on the base
can be protected as necessary or desired. Suitable protecting
groups are well known to those skilled in the art, and include
trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and
t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as
acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
[0033] The term "amino acid" includes naturally occurring and
synthetic .alpha., .beta. .gamma. or .delta. amino acids, and
includes but is not limited to, amino acids found in proteins, i.e.
glycine, alanine, valine, leucine, isoleucine, methionine,
phenylalanine, tryptophan, proline, serine, threonine, cysteine,
tyrosine, asparagine, glutamine, aspartate, glutamate, lysine,
arginine and histidine. In a preferred embodiment, the amino acid
is in the L-configuration. Alternatively, the amino acid can be a
derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl,
phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl,
threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl,
aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl,
.beta.-alanyl, .alpha.-valinyl, .beta.-leucinyl,
.beta.-isoleucinyl, .beta.-prolinyl, .beta.-phenylalaninyl,
.beta.-tryptophanyl, .beta.-methioninyl, .beta.-glycinyl,
.beta.-serinyl, .beta.-threoninyl, .beta.-cysteinyl,
.beta.-tyrosinyl, .beta.-asparaginyl, .beta.-glutaminyl,
.beta.-aspartoyl, .beta.-glutaroyl, .beta.-lysinyl,
.beta.-argininyl or .beta.-histidinyl. When the term amino acid is
used, it is considered to be a specific and independent disclosure
of each of the esters of .alpha., .beta. .gamma. or .delta.
glycine, alanine, valine, leucine, isoleucine, methionine,
phenylalanine, tryptophan, proline, serine, threonine, cysteine,
tyrosine, asparagine, glutamine, aspartate, glutamate, lysine,
arginine and histidine in the D and L-configurations.
[0034] The term "pharmaceutically acceptable salt or prodrug" is
used throughout the specification to describe any pharmaceutically
acceptable form (such as an ester, phosphate ester, salt of an
ester or a related group) of a compound which, upon administration
to a patient, provides the active compound. Pharmaceutically
acceptable salts include those derived from pharmaceutically
acceptable inorganic or organic bases and acids. Suitable salts
include those derived from alkali metals such as potassium and
sodium, alkaline earth metals such as calcium and magnesium, among
numerous other acids well known in the pharmaceutical art.
Pharmaceutically acceptable salts may also be acid addition salts
when formed with a nitrogen atom. Such salts are derived from
pharmaceutically acceptable inorganic or organic acids, such as
hydrochloric, sulfuric, phosphoric, acetic, citric, tartaric, and
the like. Pharmaceutically acceptable prodrugs refer to a compound
that is metabolized, for example hydrolyzed or oxidized, in the
host to form the compound of the present invention. Typical
examples of prodrugs include compounds that have biologically
labile protecting groups on a functional moiety of the active
compound. Prodrugs include compounds that can be oxidized, reduced,
aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed,
dehydrolyzed, alkylated, dealkylated, acylated, deacylated,
phosphorylated, dephosphorylated to produce the active
compound.
(i) Synthesis of 3,5-Di-O-protected-D-ribono-.gamma.-lactone
[0035] Wittig reaction of 2,3-O-isopropylidene-D-glyceraldehyde 39
(Scheme 4) with commercially available 40 affords the (E)-product
41 as a major product. Sharpless dihydroxylation (J. Org. Chem.
1992, 57, 2768-2771) using AD-mix-.beta. as a dihydroxylation
reagent gives only the desired product 42 in very high yield. High
yield lactonization of 42 to 2-C-methyl-D-arabino-.gamma.-lactone
(46) is achieved by HCl/MeOH treatment. Selective O-benzoylation of
primary and secondary OH groups yields 3,5-di-O-benzol derivative
47 in high yield. Treatment of 47 with DAST or Deoxofluor,
[bis(2-methoxyethyl)amino]sulfur trifluoride, under various
conditions gives trace amounts of the desired
2'-fluoro-ribono-.gamma.-lactone 49, but mostly a mixture from
which the non-fluorinated ribonolactone (48) is isolated. However,
treatment of 47 with excess, preferably three (3) equivalents, of
tertiary amine, preferably diisopropylethylamine, and excess,
preferably five (5) equivalents, of DAST or Deoxofluor provides 49
in .about.50% yield. It was also found that using 3,5-O-MOM instead
of benzoyl protection, the yield of 48 approaches 90%. Thus,
treatment of 46 with dimethoxymethane in the presence of strong
acid such as trifluoromethylsulfonic acid affords 50, which upon
reaction with DAST or Deoxofluor in the presence of base yielded
87% isolated yield of 49.
[0036] It was also discovered that smooth fluorination can occur
upon treatment of the open-chain monobenzoate 43, which can be
readily obtained by selective benzoylation of 42, with DAST or
Deoxofluor giving rise to the desired ethyl
2-deoxy-2-fluoro-2-C-methyl-3-O-benzoyl-4,5-O-isopropylidene-D-ribonate
44. Lactonization of 44 gives only the .gamma.-lactone 45. Further
benzoylation of 45 affords dibenzoate 49.
##STR00007##
[0037] In one embodiment of the present invention, a method is
provided for the synthesis of intermediate 49 through Reformatsky
condensation of 39 with an alkyl 2-bromopropionate such as 53
(Scheme 5) in the presence of activated zinc in an ethereal solvent
such as diethyl ether or tetrahydrofuran (or a mixture of the two
solvents) to give 54, which is converted to 55 by oxidation.
Possible oxidizing agents are: activated dimethylsulfoxide, such as
a mixture of dimethylsulfoxide, trifluoroacetic anhydride or acetic
anhydride (a Swern/Moffat oxidation); chromium trioxide or other
chromate reagent; Dess-Martin periodinane; or tetrapropylammonium
perruthenate (TPAP) with or without molecular sieves. This
oxidation to provide the C-3 ketone preferably proceeds without
affecting the stereochemistry at C-4.
[0038] Fluorination of 55 is performed at the 2-position using an
electrophilic fluorination ("F+") in an appropriate solvent such as
dimethylformamide, tetrahydrofuran, ethanol, tert-butanol, or
diethyl ether or any combination of these solvents known to those
skilled in the art (Rozen, et. al., J. Org. Chem., 2001, 66,
7646-7468; Jun-An Ma and Dominique Cahard, Journal of Fluorine
Chemistry, 2004, in press, and references cited therein), to afford
56. Some non-limiting examples of electrophilic fluorinating
reagents are Selectflour.RTM., N-fluorosulfonimide (NFSI), and
AcOF. Stereoselective fluorination can be achieved by using a
catalyst such as an asymmetric transition metal complex catalyst as
taught by Sodeoka, et al. (JP2004010555) or by other catalysts. The
starting .beta.-keto ester 55 may also be first converted to a
ketene silyl acetal prior to fluorination (Rozen, et. al., J. Org.
Chem., 2001, 66, 7646-7468).
[0039] Selective reduction of the C-3 ketone 56 using
triphenylsilane in the presence of a Lewis acid such as AlCl.sub.3
or in the presence of an organic acid such as trifluoroacetic acid
(Kitazume, et al., J. Org. Chem., 1987, 52, 3218-3223) provides two
2,3 anti products 57 and 58. However, by utilizing a
stereoselective fluorination combined with the selective reduction,
a good yield (with high diastereomeric excess) of 58 can be
achieved. Benzoylation of 58 gives 44 which is converted to lactone
45 as described earlier.
##STR00008##
(ii) Preparation of Nucleosides Containing
2-deoxy-2-fluoro-3-methyl-D-ribofuranosyl Moiety by
Condensation
[0040] A lactone such as 49 can be reduced to the corresponding
sugar with DIBAL-H. After acetylation of the anomeric hydroxyl
group, 59 (Scheme 12) is obtained in high yield. Condensation of 59
with silylated base (e.g., silylated N.sup.4-benzoylcytosine under
Vorbruggen's conditions) affords a mixture of protected anomeric
nucleosides 60 and 60-a. After separation of the anomers, the
desired .beta.-nucleoside 14 is prepared by deprotection with metal
alcoholate in alcohol, preferably NaOMe/MeOH, or methanolic
ammonia.
##STR00009##
[0041] Compound 59 can be converted into the bromo sugar 61,
(Scheme 7) which is condensed with a sodium salt of purine, e.g.,
sodio-N6-benzoyladenine to give the corresponding protected purine
nucleoside 62. The desired free nucleoside 63 is readily obtainable
by saponification.
##STR00010##
(iii) Synthesis from Preformed Nucleosides
[0042] Using preformed nucleosides as starting materials for
preparation of the desired
2'-C-alkyl-2'-deoxy-2'-fluoro-.beta.-D-ribonucleosides has certain
advantages, as the formation of anomers and their subsequent
separation can be circumvented, resulting in high yields of the
targeted nucleosides.
[0043] Two procedures to prepare the desired nucleoside 14 from
nucleoside starting materials have been disclosed (Schemes 2 and
3). As mentioned earlier, however, these procedures also produced
two undesirable products 22 and 23, the latter produced by
neighboring group participation as shown in Scheme 8. The
separation of the desired nucleoside 14 from the mixture is rather
cumbersome. Thus, this invention prevents production of 23 using
non-participating protecting group, such as THP, methyl, ethyl,
benzyl, p-methoxybenzyl-, benzyloxymethyl, phenoxymethyl,
methoxymethyl, ethoxymethyl, mesyl, tosyl, trifluoroacetyl,
trichloroacetyl, at the 3'-OH group.
##STR00011##
[0044] An example is shown in Scheme 17. When
N.sup.4,5'-O-dibenzoyl-3'-O-mesyl-2'-deoxy-2'-C-methyl-.beta.-D-arabinofu-
ranosylcytosine (64) is treated with DAST or Deoxofluor, the
desired fluorinated product 65 is obtained in 54% yield along with
the olefin 66 in 39% yield. As expected, no unfluorinated cytidine
derivative 67 is formed in detectable amounts. There are several
ways to de-protect 65 to 14. An example is shown in Scheme 9 that
requires a double inversion of the 3'-configuration.
##STR00012##
[0045] When the 3'-O-substituent is a non-participating and
non-leaving group, such as methoxymethyl (MOM), methyl, benzyl,
methoxybenzyl or tetrahydropyranyl, the intermediate is fluorinated
more effectively than 64.
[0046] The following examples are presented to illustrate the
present invention but are not to be limited thereto.
[0047] Experimental: 2,3-O-Isopropylidene-D-glyceraldehyde (39) is
prepared by literature procedures (Organic Synthesis, Annual Volume
72, page 6; J. Org. Chem. 1991, 56, 4056-4058) starting from
commercially available protected D-mannitol. Other reagents,
including 40 and AD-mix-.beta., are from commercial sources.
EXAMPLES
Example 1
Ethyl
trans-2,3-dideoxy-4,5-O-isopropylidene-2-C-methyl-D-glycero-pent-2-e-
nonate (41)
[0048] To a solution of (carbethoxyethylidene)triphenylphosphorane
(40, 25 g, 69 mmol) in dry CH.sub.2Cl.sub.2 (65 mL) at room
temperature is added dropwise a solution of
2,3-O-isopropylidene-D-glyceraldehyde (39, 9.41 g, 72.3 mmol) in
CH.sub.2Cl.sub.2 (30 mL). The mixture is stirred at room
temperature overnight. The reaction mixture is then concentrated to
dryness, diluted with light petroleum ether (300 mL), and kept at
room temperature for 2 h. Triphenylphosphine oxide precipitated is
removed by filtration and an aliquot is concentrated in vacuo. The
residue is purified by silica gel column chromatography with 0-1.5%
EtOAc in hexanes to give 41 (10.4 g, 71%) as an oil (Carbohydrate
Res., 115, 250-253 (1983)). .sup.1H NMR (CDCl.sub.3) .delta. 1.30
(t, J=6.8 Hz, 3H, --OCH.sub.2CH.sub.3), 1.41 (s, 3H, CH.sub.3),
1.45 (s, 3H, CH.sub.3), 1.89 (d, J=1.2 Hz, 3H, 2-CH.sub.3), 3.63
(t, J=8.0 Hz, 1H, H-5), 4.14-4.23 (m, 3H, H-5' and
--OCH.sub.2CH.sub.3), 4.86 (dd, J=7.6 and 13.6 Hz, 1H, H-4), 6.69
(dd, J=1.6 and 8.0 Hz, 1H, H-3),
Example 2
(2S,
3R)-3-[(4R)-2,2-Dimethyl-[1,3]dioxolan-4-yl]-2,3-dihydroxy-2-methyl-p-
ropionic acid ethyl ester (42)
[0049] A round-bottomed flask, equipped with a magnetic stirrer, is
charged with 25 mL of t-BuOH, 25 mL of water, and 7.0 g of
AD-mix-.beta.. Stirring at room temperature produced two clear
phases; the lower aqueous phase appears bright yellow.
Methanesulfonamide (475 mg) is added at this point. The mixture is
cooled to 0.degree. C. whereupon some of the dissolved salts
precipitated, 1.07 g (5 mmol) of 41 is added at once, and the
heterogeneous slurry is stirred vigorously at 0.degree. C. for 24
h. After this time, while the mixture is stirred at 0.degree. C.,
solid sodium sulfite (7.5 g) is added and the mixture allowed to
warm to room temperature and stirred for 30-60 min. EtOAc (50 mL)
is added to the reaction mixture, and after separation of the
layers, the aqueous phase is further extracted with EtOAc. The
organic layer is dried over Na.sub.2SO.sub.4 and concentrated to
dryness. The residue is purified by silica gel column
chromatography with 20% EtOAc in hexanes to provide 42 (1.13 g,
91%) as a solid. .sup.1H NMR (DMSO-d.sub.6) .delta. 1.18 (t, J=6.8
Hz, 3H, --OCH.sub.2CH.sub.3), 1.24 (s, 3H, CH.sub.3), 1.25 (s, 3H,
CH.sub.3), 1.28 (s, 3H, 2-CH3), 3.67 (t, J=7.2 Hz, 1H), 3.85, 4.06
and 4.12 (m, 4H), 4.96 (s, 1H, 2-OH, D.sub.2O exchangeable), 5.14
(d, J=7.6 Hz, 2-OH, D.sub.2O exchangeable). Anal. Calcd for
C.sub.11H.sub.20O.sub.6: C, 53.22; H, 8.12; Found: C, 53.32; H,
8.18.
Example 3
(2S,
3R)-3-[(4R)-2,2-Dimethyl-[1,3]dioxolan-4-yl]-3-benzoyloxy-2-hydroxy-2-
-methylpropionic acid ethyl ester (43)
[0050] To a solution of compound 42 (245 mg, 0.99 mmol) in dry
pyridine (3 mL) is added dropwise a solution of BzCl (300 mg, 2.1
mmol) in pyridine (1 mL). After the mixture is stirred at room
temperature for 2 h, the reaction is quenched with H.sub.2O (1 mL).
The mixture is concentrated to dryness and the residue is
partitioned between CH.sub.2Cl.sub.2 and sat. NaHCO.sub.3 solution.
The organic phase is dried (anh. Na.sub.2SO.sub.4), filtered and
concentrated. The residue is purified by silica gel column
chromatography with 5% EtOAc in hexanes to give 43 (247 mg, 71%) as
a solid. Anal. Calcd for C.sub.18H.sub.24O.sub.7: C, 61.35; H,
6.86; Found: C, 60.95; H, 6.73.
Example 4
(2R,
3R)-3-[(4R)-2,2-Dimethyl-[1,3]dioxolan-4-yl]-3-benzoyloxy-2-fluoro-2--
methyl-propionic acid ethyl ester (44)
[0051] To a solution of compound 43 (36 mg, 0.102 mmol) in
anhydrous THF (1.5 mL) is added DAST or Deoxofluor (0.08 mL, 0.68
mmol) at 0.degree. C. under argon. The reaction mixture is stirred
at room temperature for 3 h, then cooled down to 0.degree. C., and
carefully treated with cold saturated NaHCO.sub.3 solution (2 mL).
The organic layer is dried over Na.sub.2SO.sub.4 and concentrated
to dryness. The residue is purified by silica gel column
chromatography with 1-3% EtOAc in hexanes to give 44 (24.6 mg, 68%)
as a syrup. HR-FAB MS; Obsd: m/z 361.1621. Calcd for
C.sub.18H.sub.23O.sub.6FLi: m/z 361.1639 (M+H).sup.+.
Example 5
3-O-Benzoyl-2-methyl-2-deoxy-2-fluoro-D-ribono-.gamma.-lactone
(45)
[0052] A mixture of compound 44 (308 mg, 0.86 mmol), MeCN (20 mL),
water (1 mL) and CF.sub.3CO.sub.2H (0.17 mL) is refluxed at
80-85.degree. C. for 3 h. The open-chain intermediate is not
isolated, but converted directly to 45 by azeotropic distillation
using a Dean-Stark water separator. The removed MeCN is replaced
with dry toluene, and the azeotropic distillation continued until
the oil bath temperature reached 130.degree. C. Stirring at
130.degree. C. is continued overnight. The mixture is then cooled
to room temperature and the solvent is removed in vacuo to give a
syrup, which is purified by silica gel column chromatography with
10-15% EtOAc in hexanes to give, after solvents evaporation, solid
45 (136 mg, 58.3%).
Example 6
3,5-Di-O-benzoyl-2-methyl-2-deoxy-2-fluoro-D-ribono-.gamma.-lactone
(49)
[0053] To a solution of 45 (60 mg, 0.224 mmol) in EtOAc (1 mL) are
added pyridine (100 mg, 1.26 mmol) and 4-dimethylaminopyridine (2.7
mg). The mixture is warmed to 60.degree. C. and BzCl (110 mg, 0.79
mmol) in EtOAc (0.4 mL) is added dropwise. After stirring for 3 h,
the mixture is cooled to 0.degree. C. and pyridine HCl salt is
filtered off. The filtrate is diluted with EtOH and the mixture is
evaporated to dryness. The residue is purified by silica gel column
chromatography with 3-6% EtOAc in hexanes to provide, after
solvents evaporation, solid 49 (75 mg, 91%).
Example 7
2-Methyl-D-arabino-.gamma.-lactone (46)
[0054] A solution of compound 42 (248 mg, 1 mmol) in 1.5 mL of EtOH
is treated with 0.3 mL of concentrated HCl. The reaction mixture is
stirred at room temperature for 2 h. The solvent is removed in
vacuo (bath temp.<45.degree. C.). The residue is co-evaporated
with toluene (3.times.10 mL) to give a residue, which is purified
by silica gel column chromatography with 70% EtOAc in hexanes.
Evaporation of solvents give oily 46 (170 mg, 105%). Anal. Calcd
for C.sub.6H.sub.10O.sub.5: C, 41.24; H, 6.22; Found: C, 41.00; H,
6.74.
Example 8
3,5-Di-O-benzoyl-2-methyl-D-arabino-.gamma.-lactone (47)
[0055] To a stirred solution of compound 46 (880 mg, 5.4 mmol) in
dry pyridine (80 mL) is added dropwise a solution of BzCl (1.73 g,
12.29 mmol) in dry pyridine (45 mL) at room temperature over a
period 75 min. The mixture is stirred for another 90 min, then
treated with MeOH (5 mL), and concentrated to dryness. The residue
is purified by silica gel column chromatography with 12-20% EtOAc
in hexanes to give 47 (1.1 g, 55%) as an oil.
Example 9
3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribonolactone
(49)
[0056] To a solution of 47 (430 mg, 1.16 mmol) in anhydrous THF (20
mL) and diisopropylethylamine (1 mL, 5.74 mmol) is added DAST or
DEOXOFLUOR (0.48 mL, 3.66 mmol) at room temperature under argon.
The reaction mixture is stirred at room temperature for 3 h, then
cooled down to 0.degree. C., and carefully treated with cold
saturated NaHCO.sub.3 solution (5 mL). The reaction mixture is
partitioned between EtOAc (100 mL) and water (20 mL). The organic
layer is dried over (Na.sub.2SO.sub.4) and concentrated to dryness.
The residue is purified by silica gel column chromatography with
3-6% EtOAc in hexanes to provide 49 (220 mg, 51%) as a solid.
Example 10
3,5-Di-O-benzoyl-2-methyl-D-ribono-lactone (48)
[0057] To a solution of 47 (160 mg, 0.432 mmol) in anhydrous
CH.sub.2Cl.sub.2 (5 mL) is added DAST or DEOXOFLUOR (0.15 mL, 1.14
mmol) at 0-5.degree. C. under argon. The reaction mixture is
stirred at 0-5.degree. C. for 1 h then at room temperature. After
24 hrs, the reaction still does not go well as there is no major
less polar product appears in the TLCs. The reaction mixture is
cooled to 0.degree. C., and carefully treated with cold saturated
NaHCO.sub.3 solution. The organic layer is dried over
Na.sub.2SO.sub.4 and concentrated to dryness. The residue is
checked by proton NMR. It shows that the major product is
3,5-dibenzoyl-2-methyl-D-ribono-.gamma.-lactone (48), which is
identical with authentic sample. Traces of 49 are detected on the
spectrum.
Example 11
3,5-Di-O-methoxymethyl-2-C-methyl-D-arabino-.gamma.-lactone
(50)
[0058] To a solution of 2-methylarabinolactone (46) (324 mg, 2
mmol) in CH.sub.2(OMe).sub.2 (30 mL) and CH.sub.2Cl.sub.2 (30 mL)
was added CF.sub.3SO.sub.3H (50 .mu.L), and the solution was
stirred at RT under argon for 14 h. The reaction was quenched by
addition of 28% NH.sub.4OH (0.1 mL), and the mixture was dried by
addition of Na.sub.2SO.sub.4. After removal of the solvent by
evaporation, the residue was purified by flash chromatography on
silica gel eluting with CH.sub.2Cl.sub.2/MeOH (95:5 to 9:1) to give
450 mg (90%) of product as a pale yellow oil. .sup.1H-NMR
(DMSO-d.sub.6): .delta. 6.10 (s, OH, D.sub.2O exchangeable), 4.70
(q, 2H, CH.sub.2), 4.62 (d, 2H, CH.sub.2), 4.30 (m, 1H, H-4), 4.20
(d, 1H, H-3), 3.80-3.65 (m, 2H, H-5), 3.30, 3.28 (2s, 6H, 2
CH.sub.3), 1.26 (s, 3H, CH.sub.3).
Example 12
3,5-Di-O-methoxymethyl-2-deoxy-2-fluoro-2-C-methyl-D-ribono-.gamma.-lacton-
e (51)
[0059] To a solution of 50 (100 mg, 0.4 mmol) in CH.sub.2Cl.sub.2
(3 mL) and pyridine (0.5 mL) at -78.degree. C. is added DAST or
DEOXOFLUOR (0.21 mL, 1.6 mmol), and the solution is stirred at
-78.degree. C. for 15 min. Then the solution is allowed to warm up
to room temperature and stirred at room temperature for 2 h. The
reaction is quenched by addition of saturated aqueous NaHCO.sub.3
(0.5 mL) and ice-water (0.5 mL), followed by CH.sub.2Cl.sub.2 (20
mL) and saturated aqueous NaHCO.sub.3 (10 mL). The aqueous layer is
extracted with CH.sub.2Cl.sub.2 twice, the combined organic layers
are washed with NaHCO.sub.3, and dried over Na.sub.2SO.sub.4. The
evaporation of the solvent gives 51 (88 mg, 87%) as a
brownish-yellow oil. .sup.1H-NMR (DMSO-d.sub.6): .delta. 4.74 (q,
J=6.9 & 18.1 Hz, 2H, CH.sub.2), 4.63 (d, J=0.77 Hz, 2H,
CH.sub.2), 4.54 (m, 1H, H-4), 4.18 (dd, J=7.8 & 20.0 Hz, 1H,
H-3), 3.86-3.71 (m, 2H, H-5), 3.34, 3.28 (2s, 6H, 2 CH.sub.3), 1.59
(d, J=24.26 Hz, 3H, CH.sub.3).
Example 13
Ethyl 4,5-O-Isopropylidene-3,4,5-trihydroxy-2-methylvalerate
(54)
[0060] To activated zinc (6.5 g, 0.10 mmol) is added about 20 mL of
a solution containing 39 (13.0 g, 0.1 mmol), 53 (13.0 mL, 0.10
mmol), THF (50 mL), and diethyl ether (50 mL). After the addition,
one crystal of I.sub.2 is added, whereby an exotherm is generated,
causing the solution to reflux. The remaining solution is added
over about 0.75 h as to maintain a gentle reflux. The mixture is
gently heated to reflux for an additional 1 h after the final
addition. The mixture is cooled to room temp, poured into ice (200
mL) and 1 N HCl (200 mL) and allowed to stir until most of the ice
had melted (about 0.5 h). The organic layer is separated and the
aqueous layer is extracted with diethyl ether (2.times.75 mL). The
combined organic layers are washed with satd NaHCO.sub.3
(1.times.150 mL), brine (1.times.150 mL), dried (Na.sub.2SO.sub.4),
filtered, and concentrated to dryness in vacuo. Further drying in
vacuo provides 54 as a mixture of diastereomers (15.1 g, 65.1%).
This compound is used without further purification.
Example 14
Ethyl 4,5-O-Isopropylidene-3-oxo-2-methylvalerate (55)
[0061] Compound 54 (9.85 g, 0.042 mol) is dissolved in dry THF (50
mL). Anhydrous DMSO (16.0 mL, 0.22 mol) is added and the resulting
solution is cooled to between -20.degree. C. and -15.degree. C.
Trifluoroacetic anhydride (9.8 mL, 0.69 mol) is added dropwise over
15 minutes and the solution is stirred between -20.degree. C. and
-15.degree. C. for 2 h after which anhydrous NEt.sub.3 (24.0 mt,
0.17 mol) is added over 20 min. The resulting solution is stirred
at room temp for 1 h, diluted with diethyl ether (50 mL), and
washed with H.sub.2O (3.times.100 mL), dried (Na.sub.2SO.sub.4) and
concentrate in vacuo to compound 55 as a yellow oil (8.1 g, 82.0%)
that is used without further purification. .sup.1H NMR (CDCl.sub.3,
400 MHz): 1.24-1.38 (m, 26H), 3.81 (q, 1.3H, J=7.3 Hz), 3.89 (q,
1.0H, J=7.3 Hz), 3.99-4.04 (m, 3H), 4.10-4.20 (m, 7H), 4.21-4.29
(m, 3H), 4.51 (dd, 1.0H, J=8.1, 6.2 Hz), 4.58 (dd, 1.3H, J=7.7, 5.0
Hz).
Example 15
Ethyl 4,5-O-Isopropylidene-2-fluoro-3-keto-2-methylvalerate
(56)
[0062] Compound 55 (7.36 g, 0.042 mol) is dissolved in anhydrous
DMF (5.0 mL) and treated with a slurry of Selectfluor (55.0 g,
0.155 mol) in DMF (45.0 mL). The mixture is placed in an oil bath
maintained at 45-50.degree. C. and the suspension is maintained
with stirring at that temperature overnight under an argon
atmosphere. The solution is concentrated to near dryness in vacuo,
treated with diethyl ether (.about.25 mL) and washed with water
(3.times.100 mL). The organic phase is dried (Na.sub.2SO.sub.4) and
concentrate in vacuo to compound 56 as a yellow oil (5.65 g, 71.2%)
that was an approximate 1:1 mixture of 2R:2S fluorinated compound
as judged by .sup.19F NMR. .sup.1H NMR (CDCl.sub.3, 400 MHz):
1.20-1.46 (m, 16H), 1.70 (2d, 3H, J=22.8 Hz), 4.05-4.10 (m, 2H),
4.12-4.32 (m, 2H), 4.90-97 (m, 1H). .sup.19F NMR (CDCl.sub.3, 376
MHz, C.sub.6F.sub.6 external standard): 4.30 (q), 4.01 (q).
Example 16
3,5-O-dipivaloyl-2-methyl-D-arabino-.gamma.-lactone (47 B)
[0063] To a solution of 42 (4 mmol, 897 mg) in EtOH (20 mL) was
added concentrated HCl (2.0 mL), and the solution stirred at room
temperature for 1 h. The solution was concentrated to dryness and
the residue was co-evaporated with THF (10 mL) and dissolved in
pyridine (6 mL) and CH.sub.2Cl.sub.2 (14 mL). The solution was
cooled in ice-bath. To the solution was added pivaloyl chloride (8
mmol, 0.98 mL) and the solution stirred at 0.degree. C. for 30 min.
To the solution was added an additional pivaloyl chloride (4 mmol,
0.49 mL) and the solution stirred at room temperature for 5 h. To
the solution was added 4-dimethylaminopyridine (100 mg) and the
solution was stirred at room temperature for 20 h. H.sub.2O (5 mL)
was added and the mixture was stirred at room temperature for 20
min. EtOAc (50 mL) was added. The mixture was washed with water,
brine and dried (Na.sub.2SO.sub.4). Solvent was removed and the
residue was recrystallized from EtOAc-Hexanes to give fine crystals
(625 mg, 47%). H-NMR (CDCl.sub.3): .delta. 5.18 (d, J=6.80 Hz, 1H,
H-3), 4.45, 4.22 (m, 2H, H-5), 4.41 (m, 1H, H-4), 3.32 (br s, 1H,
OH, D.sub.2O exchangeable), 1.43 (s, 1H, Me), 1.25, 1.22 [ss, 18H,
C(Me).sub.3].
Example 17
2-Deoxy-3,5-O-dipivaloyl-2-fluoro-2-C-methyl-D-ribono-.gamma.-lactone
(49B)
[0064] To a solution of 47B (100 mg, 0.3 mmol) in THF (5 mL) were
added EtNPr.sub.2 (2 mmol, 0.35 mL) and Deoxo-Fluor (0.18 mL, 0.9
mmol), and the solution was stirred at room temperature for 4 h. To
the solution was added additional Deoxo-Fluor (0.18 mL, 0.9 mmol)
and the solution was stirred at room temperature for 16 h, refluxed
for 1 h. EtOAc (50 mL) was added. The solution was washed with
aqueous NaHCO.sub.3, brine, dried (Na.sub.2SO.sub.4). Solvent was
removed and the residue was purified by column (10% EtOAc in
hexanes) to give product as a solid (65 mg, 65%). H-NMR
(CDCl.sub.3): .delta. 5.12 (m, 1H, H-3), 4.68 (m, 1H, H-4), 4.41,
4.18 (m, 2H, H-5), 1.63 (d, J=23.2 Hz, 1H, Me), 1.25, 1.20 [ss,
18H, C(Me).sub.3].
* * * * *